A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)

Exclusion Criteria

• •1. Platelet count greater or equal to 100\*10\^9/μL.
• •2. Severe heart, liver and kidney dysfunction, including those with glutamic-pyruvic transaminase ≥ 5xULN，glomerular filtration rate \<30ml/min.
• •3. Uncontrolled severe active infection.
• •4. Known congenital TTP.
• •5. Subjects with malignant tumors in the past 5 years.
• •6. Other diseases that cause microangiopathy hemolytic anemia and thrombocytopenia, such as disseminated intravascular coagulation (DIC), antiphospholipid antibody syndrome, hemolytic uremic syndrome, malignant hypertension, and transplant-related microangiopathy.
• •7. Pregnant or lactating women. Subjects of reproductive age, are unable to use effective contraceptive methods during the study period.
• •8. Severe active bleeding or progressive aggravation of bleeding symptoms.
• •9. Subjects who have received plasmapheresis during the treatment of the onset of the disease.
• •10. Subject is participating in other clinical stuy or is less than 3 months away from the end of previous clinical study.
• •11. Subject who have participated in other clinical trials related to Anfibatide.
• •12. Severe or life threatening clinical condition other than TTP that would impair participation in the trial.
• •13. Life expectation less than 1 week.
• •14. Known to be allergic to the drugs or ingredients in the study.
• •15. Inability to follow programme requirements and procedures.